Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures.

Pont, LG; Nielen, JTH; McLachlan, AJ; Gnjidic, D; Chan, L; Cumming, RG; Taxis, K

Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures.

Pont, LG Nielen, JTH McLachlan, AJ Gnjidic, D Chan, L Cumming, RG Taxis, K

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: British journal of clinical pharmacology, 2015, 80, (5), pp. 1169-1175
Issue Date:: 2015-11

Closed Access

	Filename	Description	Size
	2015_Pont and Nielen et al_anticholinergic exposure_BJCP.pdf	Published version	1 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Pont, LG
dc.contributor.author	Nielen, JTH
dc.contributor.author	McLachlan, AJ
dc.contributor.author	Gnjidic, D
dc.contributor.author	Chan, L
dc.contributor.author	Cumming, RG
dc.contributor.author	Taxis, K
dc.date.accessioned	2022-01-25T01:32:18Z
dc.date.available	2015-04-10
dc.date.available	2022-01-25T01:32:18Z
dc.date.issued	2015-11
dc.identifier.citation	British journal of clinical pharmacology, 2015, 80, (5), pp. 1169-1175
dc.identifier.issn	1365-2125
dc.identifier.issn	1365-2125
dc.identifier.uri	http://hdl.handle.net/10453/153539
dc.description.abstract	Anticholinergic drug exposure is associated with adverse outcomes in older people. While a number of tools have been developed to measure anticholinergic drug exposure, there is limited information about the agreement and overlap between the various scales. The aim of this study was to investigate the agreement and overlap between different measures of anticholinergic drug exposure in a cohort of community-dwelling older men.A cross-sectional study was used to compare anticholinergic drug exposure calculated using the Anticholinergic Risk Scale (ARS), the Anticholinergic Drug Scale (ADS), the Anticholinergic Cognitive Burden (ACB) and the Drug Burden Index anticholinergic subscale (DBI-ACH) in a cohort of community-dwelling men aged 70 years and older (n = 1696). Statistical agreement, expressed as Cohen’s kappa (κ), between these measurements was calculated.Differences were found between the tools regarding the classification of anticholinergic drug exposure for individual participants. Thirteen percent of the population used a drug listed as anticholinergic on the ARS, 39% used a drug listed on the ADS and the ACB, and 18% of the population used one or more anticholinergic drugs listed on the DBI-ACH. While agreement was good between the ACB and ADS (κ = 0.628, 95% CI 0.593, 0.664), little agreement was found between remaining tools (κ = 0.091-0.264).With the exception of the ACB and ADS, there was poor agreement regarding anticholinergic drug exposure among the four tools compared in this study. Great care should be taken when interpreting anticholinergic drug exposure using existing scales due to the wide variability between the different scales.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	British journal of clinical pharmacology
dc.relation.isbasedon	10.1111/bcp.12670
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	Cholinergic Antagonists
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Drug-Related Side Effects and Adverse Reactions
dc.subject.mesh	Humans
dc.subject.mesh	Longitudinal Studies
dc.subject.mesh	Male
dc.subject.mesh	Pharmaceutical Preparations
dc.subject.mesh	Humans
dc.subject.mesh	Cholinergic Antagonists
dc.subject.mesh	Pharmaceutical Preparations
dc.subject.mesh	Longitudinal Studies
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	Male
dc.subject.mesh	Drug-Related Side Effects and Adverse Reactions
dc.title	Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures.
dc.type	Journal Article
utslib.citation.volume	80
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-01-25T01:32:17Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	80
utslib.citation.issue	5

Abstract:

Anticholinergic drug exposure is associated with adverse outcomes in older people. While a number of tools have been developed to measure anticholinergic drug exposure, there is limited information about the agreement and overlap between the various scales. The aim of this study was to investigate the agreement and overlap between different measures of anticholinergic drug exposure in a cohort of community-dwelling older men.A cross-sectional study was used to compare anticholinergic drug exposure calculated using the Anticholinergic Risk Scale (ARS), the Anticholinergic Drug Scale (ADS), the Anticholinergic Cognitive Burden (ACB) and the Drug Burden Index anticholinergic subscale (DBI-ACH) in a cohort of community-dwelling men aged 70 years and older (n = 1696). Statistical agreement, expressed as Cohen’s kappa (κ), between these measurements was calculated.Differences were found between the tools regarding the classification of anticholinergic drug exposure for individual participants. Thirteen percent of the population used a drug listed as anticholinergic on the ARS, 39% used a drug listed on the ADS and the ACB, and 18% of the population used one or more anticholinergic drugs listed on the DBI-ACH. While agreement was good between the ACB and ADS (κ = 0.628, 95% CI 0.593, 0.664), little agreement was found between remaining tools (κ = 0.091-0.264).With the exception of the ACB and ADS, there was poor agreement regarding anticholinergic drug exposure among the four tools compared in this study. Great care should be taken when interpreting anticholinergic drug exposure using existing scales due to the wide variability between the different scales.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/153539